IGF1R and Miyoshi myopathy: A few selective inhibitors to the IGF-1R (antagonistic antibodies) or its kinase activation domain (small synthetic RTK inhibitors) have been described, some of these tested also in early clinical trials for solid tumors and MM (62,63).